Navigation Links
Lapatinib shows minimal effect against liver cancer
Date:9/8/2009

PHILADELPHIA Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

Findings of this phase II, multi-institutional study are published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"These results may not be practice changing, but they do emphasize the need to continue developing strategies targeting epidermal growth factor receptor [EGFR] in hepatocellular carcinoma," said lead researcher Tanios Bekaii-Saab, M.D., assistant professor of medicine and pharmacology and medical director of gastrointestinal oncology at the Ohio State University Comprehensive Cancer Center.

The prevalence of hepatocellular carcinoma is increasing worldwide, and since this form of cancer typically responds poorly to chemotherapy, new treatments are necessary to help curb its rise. The current standard treatment for advanced hepatocellular carcinoma is sorafenib.

This study is one of the first trials to test the tolerability and efficacy of lapatinib in patients with advanced hepatocellular carcinoma. Lapatinib targets both EGFR and Human EGFR type 2 (HER2/neu) signaling pathways. The FDA approved this drug in March of 2007 for patients with breast cancer who were already using the chemotherapeutic agent capecitabine. Lapatinib works by inhibiting the tyrosine kinase activity associated with the two oncogenes EGFR and HER2/neu.

Twenty-six patients with advanced hepatocellular carcinoma received 1,500 mg/d of lapatinib by mouth for 28 days. Bekaii-Saab and colleagues evaluated tumor and blood specimens for expression of these signaling pathways. '/>"/>

Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. New research shows how chronic stress worsens neurodegenerative disease course
5. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
6. Circulating fats kill transplanted pancreas cells, study shows
7. New Heart Pump Shows Promise in Trial
8. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
9. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
10. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
11. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lapatinib shows minimal effect against liver cancer
(Date:5/27/2015)... 27, 2015 Cincinnati Veterans Affairs Women’s Health ... Veterans (CERV) Foundation is proud to host the first annual ... Veterans June 11 at the Freedom Center from 6 p.m. ... be the emcee. , This event honors and celebrates ... nation. The banquet is free to the first 150 ...
(Date:5/27/2015)... May 27, 2015 Genius Monkey is ... advanced programmatic marketing technology, they have boosted sales for ... on a regional level for seven Utah-based dealers. ... through television and radio media. In 2014 the Utah ... help of Genius Monkey , shifted their marketing ...
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 With ... total communication environment where the message is not only heard ... toy, drawing, or virtually any motivating image. This award-winning and ... to offer. , Now, using InnerVoice Sender app ... can be sent to a learner remotely for no additional ...
(Date:5/27/2015)... May 27, 2015 With a prevalently ... poll conducted during the "ACA - Controlling the Chaos" ... 75% are currently in the process of researching ... were confidently prepared for the reporting mandates. , According ... the webinar, those who are currently vetting ACA reporting ...
(Date:5/27/2015)... SmarterSkin, http://www.smarterskindermatology.com , is taking skin care ... makes it easier for patients to find skin care products ... Sejal Shah is a cosmetic dermatologist based in New York ... test. This revolutionary DNA test uses 16 genetic markers to ... , 1. Firmness and elasticity , 2. Glycation , ...
Breaking Medicine News(10 mins):Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Employers are On Track for ACA Reporting According to Businessolver Poll 2Health News:SmarterSkin Dermatology is Now Offering Skin DNA Analysis 2
... with language problems might have a lot in common with ... Impairment (SLI) // and they feel that these findings could ... best treatments for individual components of the condition. ,Researchers ... key language center in the brain -- in autistic boys ...
... your child at bedtime would be a pitch-black room as ... risk for leukemia.// ,In the past, research has ... for breast cancer, further supporting the theory that light at ... determined that light at night is found to disrupt the ...
... loss may also help prevent prostate cancer from spreading. A ... spread of cancer to the bone and reduce the risk ... bone loss. ,Estimates show prostate cancer spreads to the ... 311 men who were being given hormone therapy for bone ...
... worth of data on breast cancer patients , researchers say ... at diagnosis and those who are diagnosed at a younger ... to die from the disease. Black women are also more ... are those whose tumors are negative for the estrogen receptor. ...
... 2 diabetes could benefit from statins to reduce their risk ... benefits of statin therapy to reduce cardiovascular disease in // ... diabetics who are at an increased cardiovascular risk would benefit ... to look at the effectiveness of statin therapy among type ...
... who have implanted heart-assist devices, such as pacemakers ... .// ,Pacemakers and defibrillators are battery-operated implantable ... as arrhythmia. Researchers say doctors have feared that ... up metal components of the device, dislodge it, ...
Cached Medicine News:
(Date:5/27/2015)... -- Actavis plc (NYSE: ACT ) announced today ... and Drug Administration (FDA) as a twice-daily, oral ... with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid ... a delta receptor antagonist, and a kappa receptor ... "The FDA,s approval of VIBERZI is ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... May 27, 2015 The prevalence of cardiovascular ... accelerated aging of population and changes in consumption concept, ... been growing year after year, thereby promoting the development ... in China totaled 454,505 in ... interventional cardiovascular device industry there was worth RMB20.12 billion. ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3
... Alere Health, LLC announced today that it has ... Health Information Products Certification for Health Information Line. ... a 24/7 nurseline staffed by highly experienced, registered ... decisions by providing immediate clinical support for everyday ...
... BOTHELL, Wash., April 6, 2011 BioLife Solutions, Inc. ... grade biopreservation media products for cells and tissues, today ... ended March 31, 2011. This represents 6% sequential growth ... growth from the first quarter of 2010.   ...
Cached Medicine Technology:Alere Earns NCQA Health Information Products Certification for Health Information Line 2BioLife Solutions Announces Record Quarterly Revenue 2BioLife Solutions Announces Record Quarterly Revenue 3BioLife Solutions Announces Record Quarterly Revenue 4
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: